NJ drugmaker faces civil, criminal fines over drug

by Linda A. Johnson

(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

Officials from Woodcliff Lake-based Par Pharmaceutical Cos. pleaded guilty to a charge of criminal misbranding Tuesday in federal court in Newark.

Par officials admitted they improperly marketed their Megace ES drug for treating anorexia and malnutrition in geriatric patients who did not have AIDS. It's approved for helping .

The company has also agreed to enter into a five-year corporate integrity agreement with and to drop a lawsuit it filed against the U.S. government.

Par agreed in July to be acquired by an affiliate of the private investment firm TPG for $1.84 billion.

0 shares

Related Stories

SAP to pay $20M to settle criminal charges

date Sep 15, 2011

(AP) -- Business software maker SAP AG on Wednesday said it agreed to pay $20 million to settle criminal charges from the U.S. Department of Justice against a now-defunct subsidiary, TomorrowNow.

Novartis fined $422.5M in marketing, kickback case

date Sep 30, 2010

(AP) -- Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, ...

Recommended for you

Teva to lift bid for Mylan: report

date 22 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

date Jul 06, 2015

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.